<DOC>
	<DOCNO>NCT01794793</DOCNO>
	<brief_summary>The purpose study allow continue use pasireotide patient pasireotide treatment Novartis-sponsored , Oncology Clinical Development &amp; Medical Affairs ( CD &amp; MA ) study benefit treatment judge investigator .</brief_summary>
	<brief_title>Study Allow Access Pasireotide Patients Benefiting From Pasireotide Treatment Novartis-sponsored Study .</brief_title>
	<detailed_description>This multi-center , open label , phase IV study provide continue supply pasireotide patient treat current Novartis-sponsored , Oncology CD &amp; MA study benefit treatment pasireotide . Eligible patient consent continue treatment pasireotide protocol . All patient schedule visit drug dispense information report adverse event serious adverse event collect . A patient reach end study pasireotide treatment permanently discontinue end treatment visit perform . All patient must follow safety evaluation 3 month follow last dose pasireotide LAR treatment 1 month follow last dose pasireotide s.c. treatment . The study expect remain open approximately 10 year time enrol patient longer need treatment pasireotide able obtain commercial supply accord local regulation medical condition .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Pituitary Diseases</mesh_term>
	<mesh_term>Pituitary Neoplasms</mesh_term>
	<mesh_term>Cardiac Complexes , Premature</mesh_term>
	<mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
	<mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
	<mesh_term>Dumping Syndrome</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Patient currently participate Novartis Oncology sponsor study receive pasireotide ( LAR and/or s.c. ) fulfil required assessment parent study ( unless study terminate ) patient benefit study drug alternative Patient currently benefit treatment pasireotide , determine investigator Patient demonstrate compliance , assess investigator , parent study requirement Willingness ability comply schedule visit , treatment plan study procedure Written inform consent obtain prior enrol rollover study receive study medication â€¢ If consent express writing , must formally document witnessed , ideally via independent trust witness Patient permanently discontinue pasireotide study treatment parent study due unacceptable toxicity , noncompliance study procedure , withdrawal consent reason Patient participate Novartis sponsor combination trial pasireotide dispense combination another study medication still receive combination therapy . ( patient receive pasireotide monotherapy include ) Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose 1 month pasireotide s.c. last dose 3 month pasireotide LAR last dose Highly effective contraception method include : Total abstinence ( line prefer usual lifestyle subject . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment Male sterilization ( least 6 month prior screen ) . For female subject study vasectomized male partner sole partner subject . Combination two follow ( a+b a+c , b+c ) : 1 . Use oral , injected implant hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) 3 . Barrier method contraception : Condom Occlusive cap diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository In case use oral contraception woman stable pill minimum 3 month take study treatment Sexually active male unless use condom intercourse take drug 1 month pasireotide s.c. last dose 3 month pasireotide LAR last dose father child period . A condom require use also vasectomize men order prevent delivery drug via seminal fluid If study patient partner become pregnant suspect pregnant study within 1 month final dose pasireotide s.c. 3 month final dose pasireotide LAR , Study Doctor need inform immediately ongoing study treatment pasireotide stop immediately For patient take pasireotide LAR , future dose injection cancel .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>SOM230 ,</keyword>
	<keyword>roll-over study</keyword>
	<keyword>pasireotide LAR</keyword>
	<keyword>Cushing 's disease</keyword>
	<keyword>Acromegaly</keyword>
	<keyword>neuroendocrine tumorsNETs</keyword>
	<keyword>pituitary tumor</keyword>
	<keyword>Ectopic ACTH secrete</keyword>
	<keyword>EAS</keyword>
	<keyword>Dumping Syndrome</keyword>
	<keyword>metastatic prostate cancer , metastatic melanoma</keyword>
	<keyword>bRAF</keyword>
	<keyword>nRAS</keyword>
</DOC>